TRT Aveed denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for trt aveed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applied a Quantity Limit to Aveed

Humana's quantity-limit denial means the number of Aveed (testosterone undecanoate long-acting injection) doses prescribed or dispensed in a given period exceeds the quantity their formulary policy allows without additional review. Quantity limits for long-acting injectable testosterone are typically tied to the dosing interval specified in the FDA-approved prescribing label — if the claimed quantity corresponds to a dosing schedule that differs from the label's standard interval, Humana's system may automatically deny the overage.

## Why This Denial Is Appealable

If the prescribed quantity reflects the FDA-approved dosing regimen as outlined in the current prescribing label, the denial is directly rebuttal-ready. If the quantity reflects a clinically modified interval ordered by the physician based on therapeutic monitoring (e.g., trough levels guiding the interval), the appeal must document that clinical rationale explicitly. Quantity-limit denials are a defined category of adverse determination subject to full appeal rights.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Humana must respond within 30 days (standard) or 72 hours (expedited).
• Quantity-limit exception: Humana's formulary exception process allows a prescriber to request an exception to standard quantity limits when the standard quantity is medically inadequate for a specific patient.
• External review (ACA §2719 / ERISA §503): After the internal appeal, you have approximately 4 months to request binding independent external review.

## Documentation to Gather

1. FDA-approved prescribing label — Download the current Aveed label from DailyMed. The label defines the approved dosing interval. If the prescribed quantity matches the label's standard regimen, cite this directly in the appeal. 2. Physician dosing rationale — If the prescribed interval differs from the label's standard, the prescriber must document: the clinical reason for the modified schedule, the therapeutic monitoring results (e.g., testosterone level trends) that informed the adjustment, and the clinical risk of under-treatment at the standard quantity. 3. Diagnosis and treatment history — Chart confirmation of hypogonadism diagnosis, duration of testosterone therapy, and response to treatment. 4. Prescriber letter — Explicitly addresses how the prescribed quantity relates to the FDA-approved label and, if different, the individualized clinical rationale. Should also reference the applicable Endocrine Society monitoring guidance (organization reference only). 5. Administration records — Because Aveed is administered in a clinical setting under the REMS program, administration logs from the prescriber's office confirm the actual injection schedule and support the quantity requested.

## Criteria-Mapping Structure

| Quantity Limit Issue | Supporting Documentation | |---|---| | Prescribed quantity vs. Humana limit | Comparison of PA request to Humana's published limit | | FDA label dosing interval | Relevant section of prescribing label | | Clinical rationale if modified schedule | Prescriber note + monitoring results from chart | | Risk of reduced quantity | Prescriber's clinical assessment of under-treatment risk |

Before filing, confirm with your prescriber's billing staff that the drug was coded with the correct NDC and units — quantity-limit triggers can sometimes result from coding errors (e.g., units entered as vials vs. doses). A corrected claim submission may resolve the issue without a formal appeal.